IFIH1 and COVID-19: A large retrospective cohort study conducted during the Omicron-predominant period found that, compared to other IIM subtypes-particularly ASS, patients with anti-MDA5+ DM did not exhibit a higher risk of COVID-19-related hospitalization, severe disease, or mortality (48).